Jaffer Shahab

How does it work?  

Choose a discussion topic. Interact with your peers and identify novel approaches to the challenge confronting you. Each roundtable is led by a subject matter expert. A 10-minute feedback session will follow the discussions, where the roundtable leaders will share the key findings. 

• TABLE A - From Capability Assessment to Cultural Fit: Factors to Consider When Selecting the Right CDMO 
• TABLE B - The Regulatory Radar: What Should Be on Your Watchlist? 
• TABLE C - Most Favoured Nation Pricing: What Does It Mean for Global Drug Access and Manufacturing? 
• TABLE D - The Lifecycle Balancing Act: Managing Commercial Expectations for Established Medicines 
• TABLE E - Do Penalty Clauses Build Better Partnerships...or Break Them? 
• TABLE F - How Mid-Sized CDMOs Can Attract Big Pharma 

As pharmaceutical companies increasingly rely on CDMOs to deliver complex therapies and expand manufacturing capacity, strong partnerships have never been more critical. These relationships play a vital role in ensuring life-saving medicines reach patients safely and on time. 

• In your opinion, what are the three most important qualities of a successful pharma–CDMO partnership?
• How can both parties navigate challenges around cost, quality, risk, and ownership while maintaining trust?
• To share lessons learned from partnerships that succeeded (or failed) and how have those experiences shaped future collaborations?